Best Practices for Formulation and Manufacturing of Biotech Drug Products - How to maintain product stability and prevent particulates. - BioPharm International

ADVERTISEMENT

Best Practices for Formulation and Manufacturing of Biotech Drug Products
How to maintain product stability and prevent particulates.


BioPharm International
Volume 22, Issue 6

16. Matveev YI, Ablett S. Calculation of the Cg' and Tg' interaction point in the state diagram of frozen solutions. Food Hydrocolloids. 2002;16:419–22.

17. Strambini GB, Gabellieri E. Proteins in frozen solutions: evidence of ice-induced partial unfolding. Biophys J. 1996;70:971–76.

18. Shalaev E, Franks F. Solid-liquid state diagrams in pharmaceutical lyophilisation: crystallisation of solutes, progress in amrophous food and pharmaceutical systems. Levine H, editor. UK: The Royal Society of Chemistry; 2002. p. 200–15

19. Chang BS, Randall CS. Use of subambient thermal analysis to optimize protein lyophilization. Cryobiol. 1992;29:632–56.

20. Carpenter JF, Pikal MJ, Chang BS, Randolph TW. Rational design of stable lyophilized protein formulations: some practical advice. Pharm Res. 1997;14:969–75.

21. Webb SD, Webb JN, Hughes TG, Sesin DF, Kincaid AC. Freezing biopharmaceuticals using common techniques—and the magnitude of bulk-scale freeze-concentration. BioPharm Int. 2002;15:22–34.

22. Lashmar UT, Vanderburgh M, Little SJ. Bulk freeze-thawing of macromolecules. Effect of cryoconcentration on their formulation and stability. BioProcess Int. 2007;5:44–54.

23. Peters EN. Plastics: thermoplastics, thermosets and elastomers. In: M Kutz, editor. Handbook of materials selection. New York: John Wiley and Sons; 2002. p. 336–37.

24. Eisai Machinery U.S.A. Inc. [homepage on the Internet]. Available from: http://www.eisaiusa.com/

25. Brevetti CEA [homepage on the Internet]. Available from: http://www.brevetti-cea.com/

26. Seldenader [homepage on the Internet]. Available from: http://www.seidenader.de/

27. Knapp JZ, Abramson LR. Automated particulate inspection systems: strategies and implications. J Pharm Sci Technol.1990;44:74–107.

28. Knapp JZ. Overview of the forthcoming PDA task force report on the inspection for visible particles in parenteral products: practical answers to present problems. J Pharm Sci Technol. 2007;75:131–47.

29. Cromwell MEM, Hilario E, Jacobson F. Protein aggregation and bioprocessing. AAPS J. 2006;8(3):E572–79.

30. Sharma DK, et al. Flow microscopy for particulate analysis in parenteral and pharmaceutical fluids. Euro J Parent Pharma Sci. 2007;12(4):97–101.

31. Jones LS, Kaufmann A, Middaugh CR. Silicone oil induced aggregation of proteins. J Pharm Sci. 2005;94(4):918–27.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

NIH Seeks to Improve Vaccine Response with New Adjuvants
September 30, 2014
New Report Details Players and Pipelines in the Biosimilar Space
September 30, 2014
Baxter International Plans to Open R&D Center for Baxalta
September 30, 2014
FDA Releases First-Ever Purple Book for Biosimilar Characterization
September 26, 2014
FDA and NIH Win Award for IP Licensing of Meningitis Vaccine
September 26, 2014
Author Guidelines
Source: BioPharm International,
Click here